Ketamine Routes for TRD: Efficacy, Safety, and Dosing Insights

Ketamine Administration Routes in TRD

Treatment-resistant depression (TRD) presents a significant challenge in mental health care, characterized by substantial functional impairment and increased suicide risk. Ketamine, a rapid-acting glutamatergic treatment, has shown promise in addressing TRD, with various administration routes offering differing efficacy and safety profiles. A recent review synthesizes evidence on these routes, emphasizing the need for further comparative trials and safety monitoring.

Mechanisms and Context of Ketamine Use

Ketamine and its S-enantiomer, esketamine, can be administered via intravenous (IV), intranasal (IN), oral, subcutaneous (SC), and intramuscular (IM) routes. IV racemic ketamine is noted for its strong and rapid antidepressant effects, necessitating infusion-suite equipment and monitoring due to potential side effects like transient hypertension and dissociation. IN esketamine, approved by the U.S. Food and Drug Administration (FDA), offers robust long-term data but requires in-clinic administration and blood pressure monitoring.

Policy and Research Implications

The review underscores the importance of context in choosing the optimal ketamine route, balancing efficacy, safety, cost, and health-system capacity. Oral and sublingual forms provide easier access and lower cost but have reduced bioavailability and modest effect sizes. These may be suitable for maintenance treatment in resource-constrained settings. The review calls for direct comparative trials and extended safety monitoring to better define the long-term efficacy and tolerability of different ketamine administration routes.

Risks and Unknowns

While IV and IN routes are well-supported for rapid response, the review highlights the need for caution due to potential adverse effects. Oral and sublingual routes pose a higher risk of diversion and have limited evidence supporting their efficacy. SC and IM injections, achieving approximately 90% bioavailability, require minimal infrastructure but lack extensive supporting data. The review emphasizes that the optimal route is context-dependent, requiring careful consideration of individual patient needs and health-system capabilities.

Future Directions in Ketamine Research

Looking forward, the review advocates for further research to optimize ketamine use in TRD. This includes direct comparative trials to establish the most effective and safe administration routes, as well as extended safety monitoring to assess long-term outcomes. As the understanding of ketamine's role in TRD evolves, these insights will be crucial in guiding clinical practice and policy development.